EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial

Does the EMPEROR-Preserved prognostic model accurately stratify risk in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the FINEARTS-HF trial, and does baseline risk modify the treatment effect of finerenone?In this secondary analysis of 6001 patients from the FINEARTS-HF trial, the risk model showed good discrimination and generally preserved calibration across mortality. The relative treatment effect of finerenone was consistent across all risk categories, while absolute risk reductions were greater among patients at higher baseline risk.In this study, the EMPEROR-Preserved risk model provided a practical framework for risk stratification and estimation of absolute treatment benefit in patients with heart failure and mildly reduced or preserved ejection fraction and may support patient selection and enrichment in future clinical trials.

Corresponding Author: John J. V. McMurray, MD, Institute of Cardiovascular and Medical Sciences, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow, G12 8TA, United Kingdom (john.mcmurray@glasgow.ac.uk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.